Skip to main content
Premium Trial:

Request an Annual Quote

Toshiba to Use its DNA Chip in HIV Pharmacogenomics Study

NEW YORK, June 19 - Toshiba and the Institute of Human Virology will study ways in which a pharmacogenomics technology developed by the Japanese electronics giant can be used to improve the efficacy of HIV drugs, the partners said today.

 

The project, funded by the state of Maryland and the Tokyo-based Mitsui Global Strategic Studies Institute, will rely on Toshiba's electrochemical DNA chip, which the company said is smaller, and thus less expensive, than similar technologies.

 

Around two years ago Toshiba participated in a study that applied the chip to hepatitis C. The HCV chip, developed with the GeneCare Research Institute, was designed to analyze SNPs rather than pinpoint gene exression, and was meant to help predict the effectiveness of interferon in individual patients. The company also intended it to help identify better treatment regimes. Toshiba and the IHV now hope to apply it HIV therapies.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.